Future Plans and Prospects Section: Assessing the Probability of Realisation

The 2025-2026 cycle for Hong Kong IPOs is placing unprecedented scrutiny on the “Future Plans and Prospects” section of prospectuses, a shift driven by the SFC’s heightened enforcement of the Misrepresentation and Deception provisions under the Securities and Futures Ordinance (Cap. 571). Following the landmark SFC v. Ping An Securities (2024) case, where a sponsor was fined HKD 18 million for failing to verify the achievability of stated expansion plans, the market has recalibrated its risk assessment. For issuers on the Main Board and GEM, this section is no longer a boilerplate forward-looking statement; it is a binding representation of management’s intent and a key liability trigger under Listing Rule 11.07. Concurrently, the HKEX’s 2025 consultation paper on enhanced disclosure for cash-company listings has mandated that all revenue projections be backed by signed contracts or binding MOUs, not mere market reports. For IBD analysts and family office principals, the probability of realisation—the gap between a company’s stated ambitions and its operational capacity—now dictates the subscription discount applied to the final offer price. This article deconstructs the mechanics of evaluating that gap, using recent 2025 filings from biotech and consumer sectors as case studies.

The Regulatory Architecture: From Aspiration to Obligation

The SFC’s “Reasonableness” Standard Under Cap. 571

The core legal framework governing the Future Plans section is Section 107 of the Securities and Futures Ordinance (Cap. 571), which prohibits any statement that is false or misleading as to a material fact. The SFC’s 2024 enforcement action against the sponsor of a GEM-listed medical device company set a clear precedent: the regulator required the sponsor to conduct site visits to all three proposed manufacturing facilities in the PRC and verify that the company had obtained the necessary land-use rights certificates. The sponsor’s failure to do so—relying instead on a third-party market report projecting 25% annual growth in the PRC medical device market—resulted in a reprimand and a HKD 12 million fine. The SFC’s reasoning, published in its Enforcement Bulletin (January 2025), stated that “projections must be grounded in the issuer’s specific contractual and operational reality, not aggregate industry trends.”

For issuers, this means the Future Plans section must be a granular, verifiable roadmap. A typical 2025 filing for a biotech company on the Main Board, such as BioNova Therapeutics (stock code: 2555.HK), included a table breaking down its HKD 450 million capex plan into four quarters, each tied to a specific equipment purchase order (PO) number and a signed supplier agreement. The prospectus disclosed that 60% of the capex (HKD 270 million) was already subject to irrevocable letters of credit issued by a licensed PRC bank, with the remaining 40% (HKD 180 million) contingent on a Series C financing round that had a 31 March 2026 closing date. This level of specificity—down to the PO level—is now the baseline for avoiding a Section 107 challenge.

HKEX Listing Rules: The “Material Change” Trigger

Listing Rule 13.09 requires an issuer to disclose any information necessary to avoid the creation of a false market. A discrepancy between the Future Plans section and the company’s actual operational trajectory—such as a stated plan to open 50 retail stores in Tier-2 cities within 12 months, followed by a later announcement of only 12—constitutes a material change. The HKEX’s Guidance Letter GL85-16 (updated December 2024) explicitly states that the Exchange will consider a variance of more than 30% from a stated plan as prima facie evidence of a false market. This creates a direct link between the prospectus’s Future Plans and the issuer’s ongoing disclosure obligations under Chapter 13.

In practice, this means the probability of realisation is inversely correlated with the number of unqualified “may” or “intend to” statements. A 2025 filing for a PRC consumer goods company, Yuexiang Lifestyle (stock code: 1988.HK), contained a Future Plans section with 14 separate “intend to” statements—ranging from entering the Southeast Asian market to launching a private-label skincare line. The HKEX’s listing division required the company to replace 11 of those with binding commitments, such as a signed distribution agreement with a Singapore-based partner and a confirmed product development timeline from a contract manufacturer in Shenzhen. The remaining three “intend to” statements were permitted only because they were explicitly caveated with a material adverse change clause and a specific trigger event (e.g., “if the company achieves HKD 200 million in annual recurring revenue from its core business by Q3 2026”).

Financial Projections: The Devil in the Discount Rate

The Role of the Independent Business Valuer

For issuers in the biotech and pre-revenue technology sectors, the Future Plans section often includes a financial projection—typically a discounted cash flow (DCF) model—that justifies the offer price. The SFC’s Code of Conduct for Sponsors (paragraph 17.4) requires that any such projection be prepared or reviewed by an independent business valuer registered with the HKMA or a recognised professional body. The valuer must disclose the key assumptions, the discount rate, and the terminal value methodology.

A 2025 prospectus for a pre-revenue gene therapy company, GenVec Pharma (stock code: 2666.HK), included a DCF projection with a terminal value comprising 78% of the total enterprise value. The independent valuer, a Big Four firm, disclosed a discount rate of 18.5%, derived from a weighted average cost of capital (WACC) calculation that assumed a 70% probability of regulatory approval from the National Medical Products Administration (NMPA) and a 60% probability of commercial launch within 24 months of approval. The prospectus also included a sensitivity analysis showing that a 5-percentage-point increase in the discount rate (to 23.5%) would reduce the implied equity value by HKD 1.2 billion, or 34% of the pre-money valuation. For an IBD analyst, this sensitivity range is the critical input: it defines the probability of realisation. If the company’s clinical trial timeline slips by six months—a common occurrence—the discount rate effectively increases, and the implied valuation collapses.

Cash Runway and the “Going Concern” Assumption

The probability of realisation is also a function of the issuer’s cash runway. Under HKEX Listing Rule 11.07A, a Main Board applicant must demonstrate that it has sufficient working capital for at least 12 months from the date of the prospectus. The Future Plans section must reconcile the stated expansion plans with the projected cash burn. A 2025 filing for a PRC electric vehicle battery recycler, GreenCycle Metals (stock code: 2777.HK), disclosed a cash runway of 14 months post-IPO, based on a burn rate of HKD 85 million per quarter. The Future Plans section detailed a HKD 300 million capex for a new processing plant in Jiangxi Province, but the cash flow statement in the prospectus showed that the company would have only HKD 120 million in unrestricted cash after the IPO—a HKD 180 million shortfall. The company resolved this discrepancy by including a binding term sheet for a HKD 200 million credit facility from a PRC state-owned bank, with the facility’s drawdown conditions explicitly tied to the completion of the plant’s environmental impact assessment. Without this term sheet, the probability of realisation for the plant would be near zero, and the SFC would likely have required a qualified opinion from the sponsor.

Cross-Border Structures and Jurisdictional Risk

BVI, Cayman, and PRC: The Enforcement Gap

For issuers with a BVI or Cayman Islands holding company and a PRC operating entity—a standard structure for Main Board listings—the probability of realisation is heavily influenced by the enforceability of the contractual arrangements across jurisdictions. The Future Plans section must address the risk that the PRC operating entity’s assets (e.g., land-use rights, intellectual property) are not directly owned by the listed entity. A 2025 prospectus for a PRC education technology company, EduTech Global (stock code: 2888.HK), explicitly stated that its future plans to acquire 15 offline learning centres in the PRC were contingent on the BVI holding company’s ability to enforce its variable interest entity (VIE) agreements. The prospectus disclosed that the VIE agreements were governed by PRC law, but the arbitration was seated in Hong Kong under the HKIAC rules. The legal opinion from a PRC law firm, included as an exhibit, noted that a PRC court would likely enforce a HKIAC award under the Arrangement Concerning Mutual Enforcement of Arbitral Awards between the Mainland and the Hong Kong Special Administrative Region (1999), but that the process could take 12-18 months. For a family office principal, this timeline is a direct drag on the probability of realisation: any dispute with the VIE shareholders would delay the acquisition by at least a year, rendering the stated 24-month expansion plan unrealistic.

The HKMA’s Stance on Offshore Financing

The HKMA’s Supervisory Policy Manual module CA-S-1 (revised March 2025) requires that any offshore financing arrangement—such as a bridge loan from a Hong Kong-licensed bank to a BVI special purpose vehicle—must be disclosed in the Future Plans section if it is a material source of funding for the stated plans. A 2025 filing for a PRC logistics company, LogiChain Express (stock code: 2999.HK), disclosed a HKD 500 million bridge loan from a Hong Kong bank to its BVI subsidiary, with the loan’s drawdown subject to the subsidiary obtaining a specific PRC regulatory approval for a new warehouse in Guangzhou. The prospectus included a legal opinion from a PRC law firm stating that the approval was “reasonably expected” within six months, but also noted that the PRC Ministry of Commerce had recently tightened approval timelines for foreign-invested logistics projects. The probability of realisation was therefore tied to the timing of a PRC regulatory decision over which the issuer had no control. The sponsor required the company to include a sensitivity analysis showing that a six-month delay in the approval would increase the loan’s interest cost by HKD 45 million (at a floating rate of HIBOR + 300 bps), reducing the projected net profit for the first full financial year by 12%.

Actionable Takeaways for the Prospectus Reader

1. Map every “intend to” statement to a binding document: If the Future Plans section contains more than three unqualified “intend to” statements, flag the issuer for a potential SFC Section 107 challenge and demand the underlying contracts or MOUs before pricing.
2. Calculate the implied discount rate sensitivity: For any DCF projection, compute the equity value impact of a 5-percentage-point increase in the discount rate; if this reduces the valuation by more than 30%, the probability of realisation is too low to justify the stated offer price.
3. Cross-reference the cash runway with the capex timeline: If the issuer’s unrestricted cash post-IPO covers less than 80% of the stated capex for the first 12 months, require a binding credit facility or a confirmed equity injection before accepting the plan as realistic.
4. Audit the VIE enforcement timeline: For any PRC issuer with a BVI or Cayman holding company, request a legal opinion on the enforceability of the VIE agreements and calculate the minimum delay (in months) in the event of a dispute; add this delay to the stated expansion timeline.
5. Verify the sponsor’s site visit documentation: Under the SFC’s 2025 enforcement standards, the sponsor must have conducted physical site visits to all facilities referenced in the Future Plans section; request the sponsor’s due diligence report as a condition of participation in the placing.